A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia.
Started December 8, 2015
462
Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas.
Started December 8, 2015
381
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.
Started December 8, 2015
418
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial.
Started December 5, 2015
322
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results.
Started March 8, 2015
259
The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts.
Started December 9, 2014
280
Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma.
Started December 9, 2014
237
TGR-1202, a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma.
Started December 9, 2014
253
Ublituximab (TG-1101) a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL: Results of a Phase II Trial.
Started December 9, 2014
238
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma.
Started December 9, 2014
340
A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies.
Started December 10, 2013
249
The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.
Started December 10, 2013
281